Rolando Larice, MD
Psychiatry · Chesterfield, MONPI 1356324917
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 56.7% of the total. Reporting peaked in 2021 at $14,490 and has fallen 90.2% since, to $1,414 in 2025. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $59.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$12K
- Validus Pharmaceuticals LLC$2K
- Vanda Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$869
- Jazz Pharmaceuticals Inc.$708
- Neos Therapeutics, LP$530
- plus $4K from 24 others
What the payments were for
- Speaking & faculty fees$9,61946%
- Travel & lodging$2,20811%
- Food & beverage$8,86543%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 30 | $11,781 |
| Validus Pharmaceuticals LLC | 30 | $1,695 |
| Vanda Pharmaceuticals Inc. | 44 | $1,084 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $869 |
| Jazz Pharmaceuticals Inc. | 29 | $708 |
| Neos Therapeutics, LP | 39 | $530 |
| Alkermes, Inc. | 11 | $524 |
| Sunovion Pharmaceuticals Inc. | 7 | $423 |
| Neurocrine Biosciences, Inc. | 18 | $417 |
| Otsuka America Pharmaceutical, Inc. | 15 | $351 |
| Teva Pharmaceuticals USA, Inc. | 6 | $334 |
| Axsome Therapeutics, Inc. | 6 | $278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $226 |
| Eisai Inc. | 10 | $209 |
| Adlon Therapeutics L.p. | 10 | $174 |
| Tris Pharma Inc | 3 | $156 |
| Orexo US, Inc. | 7 | $132 |
| Lundbeck LLC | 8 | $128 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $123 |
| Ironshore Pharmaceuticals Inc. | 6 | $121 |
| Avanir Pharmaceuticals, Inc. | 8 | $114 |
| Shire North American Group Inc | 6 | $93 |
| Johnson & Johnson | 5 | $84 |
| Bausch Health US, LLC | 5 | $84 |
| AbbVie | 2 | $55 |
| Vertical Pharmaceuticals, LLC | 3 | $39 |
| Almatica Pharma LLC | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$7,777
- Equetro$1,241
- ARISTADA$1,000
- CAPLYTA$599
- LYBALVI$500
- LATUDA$369
- Fanapt$361
- ARISTADA INITIO$250
- SUNOSI$247
- REXULTI$125
- INGREZZA$125
- NURTEC ODT$123
- UZEDY$122
- Dyanavel XR$121
- Quillivant$121
- Quillichew ER$121
- Auvelity$118
How this compares
$20,794 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 28 | $42,626 |
| RexultiBrexpiprazole | 22 | $37,360 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 43 | $6,348 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 86 | $3,736 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 45 | $3,369 |
| EquetroCarbamazepine | 11 | $2,695 |
| Vilazodone Hcl | 22 | $2,482 |
| Lisdexamfetamine Dimesylate | 11 | $2,383 |
| Lurasidone Hcl | 22 | $2,234 |
| Lamotrigine ErLamotrigine | 12 | $1,918 |
| Clonazepam | 173 | $1,911 |
| Asenapine Maleate | 12 | $1,700 |
| Bupropion XlBupropion Hcl | 95 | $1,665 |
| Sertraline Hcl | 108 | $1,540 |
| Aripiprazole | 61 | $1,524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $55 | $42,62628 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $351 | $37,36022 claims |
| Validus Pharmaceuticals LLCEquetro | $1,695 | $2,69511 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $1,540108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Chesterfield
- Thomas HornChesterfield$15K
- Imran ChishtiChesterfield$12K
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.